Professor, Radiation Oncology, Massachusetts General Hospital, Harvard Medical School
Radiology
Dr. William U. Shipley, MD
|
|
Give Review
William U. Shipley, MD works in the field of Radiology. He graduated from Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He has 2 awards "Super Doctor" and "Top MD". William Shipley is also published. He has 76 publications published. The lastest publication: "Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study.'
Publications
- Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy...
- Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum.
- Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413.
- Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base.
- Outcomes in a Multi-institutional Cohort of Patients Treated With Intraoperative Radiation Therapy for Advanced or Recurrent Renal Cell Carcinoma.
- T1 high-grade bladder cancer recurring after BCG therapy: a curative alternative to radical cystectomy exists. Con.
- Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer.
- Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for p...
- Trimodality bladder preservation therapy for muscle-invasive bladder cancer.
- Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.
- Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
- Nomograms Predicting Response to Therapy and Outcomes After Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
- Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.
- The opportunity cost of androgen suppression in locally advanced prostate cancer.
- Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer.
- Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields.
- Words of wisdom. Re: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
- Urological cancer: The benefits of intermittent androgen-deprivation therapy.
- Reply from Authors re: Giuseppe Simone, Michele Gallucci. Multimodality Treatment Versus Radical Cystectomy: Bladder Sparing at Cost of Life? Eur Urol. In press. DOI:1...
- The importance of combined radiation and endocrine therapy in locally advanced prostate cancer.
- Complications and Long-Term Results of Salvage Cystectomy After Failed Bladder Sparing Therapy for Muscle Invasive Bladder Cancer.
- Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience.
- Radiotherapy and short-term androgen deprivation for localized prostate cancer.
- Long-Term Quality of Life Outcome after Proton Beam Monotherapy for Localized Prostate Cancer.
- Comparison of High-Dose Proton Radiotherapy and Brachytherapy in Localized Prostate Cancer: A Case-Matched Analysis.
- Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for ...
- Survivin is a potential mediator of prostate cancer metastasis.
- Acute and Late Toxicity After Dose Escalation to 82 GyE Using Conformal Proton Radiation for Localized Prostate Cancer: Initial Report of American College of Radiology...
- Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer.
- Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton ra...
- Radiation dose-volume effects of the urinary bladder.
- Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
- The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02.
- Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation th...
- Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy fol...
- Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.
- Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
- Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.
- Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413.
- Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.
- Celebrating 40 years of clinical inquiry: The RTOG'S ruby anniversary.
- Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate ...
- Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases.
- Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.
- Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.
- Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.
- Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.
- Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer.
- Radiation-sensitizing chemotherapy after transurethral resection as an alternative treatment for high-risk T1 bladder cancer.
- Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.
- Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy...
- Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy a...
- Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTR...
- PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
- Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of ...
- Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.
- Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.
- PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure.
- Defining recurrence after radiation for prostate cancer.
- Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutiona...
- Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts...
- Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation thera...
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-2004. A 57-year-old man with invasive transitional-cell carcinoma of t...
- Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
- Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis.
- RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adju...
- Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term su...
- Prostatectomy or watchful waiting in prostate cancer.
- Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy...
- Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer.
- Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.
- Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors.
- Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study.
- Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Schools
Harvard Medical School
Massachusetts General Hospital
Harvard Joint Center Rad Therapy
Royal Marsden Hospital
Doctors Specialties
- Radiation Oncology
- Radiology
Accepted Insurances
Awards
- Super Doctor
- Top MD
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Similar Doctors
|
|
Aashish D. Bhatt, MB BS
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Phillip J. Gray Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Trevor J. Royce, MD |
|
|
Dr. Stephen A. Mihalcik, MD |
|
|
Dr. Miranda B. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas J. Giacalone, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shereef M. Elnahal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lior Z. Braunstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jack E. Meyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric D. Cortell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward S. Horton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abram Recht, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David T. Miyamoto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas F. Delaney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony H. Russell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bindu N. Setty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arthur H. Baghdanian, MD
This Doctor is OpenDoctor Recommended.
|